By Fineline Cube 
Sino-US biotech AbelZeta Pharma, Inc., based in Rockville, Maryland, and with operations in Shanghai, announced that the U.S. Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation to its investigational C-CAR168. This novel dual-targeting CAR-T therapy is designed to treat refractory systemic lupus erythematosus (SLE) and lupus nephritis (LN).
C-CAR168 Innovation
C-CAR168 is an innovative autologous bi-specific CAR-T therapy targeting both CD20 and B-cell maturation antigens (BCMA). This dual-targeting approach is being developed to address autoimmune diseases, including neurological autoimmune conditions. The RMAT designation underscores the potential of C-CAR168 to significantly impact the treatment landscape for these challenging conditions.-Fineline Info & Tech